Navigation Links
ImaginAb, Inc. and GE Imanet Sign Agreement to Provide Customized, Targeted PET Imaging Agents for Drug Research
Date:10/11/2010

LOS ANGELES, Oct. 11 /PRNewswire/ -- ImaginAb, Inc. and Imanet (part of GE Healthcare) have signed a master service agreement for pre-clinical and clinical imaging. This agreement supports the development strategy for ImaginAb's pipeline of next generation diagnostic imaging agents based on recombinant antibody fragments. The Imanet™ network of Positron Emission Tomography (PET) imaging sites provides assistance in all aspects of PET imaging-based clinical trials: from proof-of-concept radiochemistry to clinical imaging, with more than 40 PET research tracers.  

"ImaginAb is pleased to have formalized this agreement with Imanet", said Dr. Christian Behrenbruch, CEO of ImaginAb. "Imanet's superb network of pre-clinical and clinical imaging sites and leveraging GE's expertise in radiochemistry will be invaluable for both our internal product pipeline as well as for ImaginAb's pharmaceutical partnerships.  We also intend to work with Imanet to validate our library of pre-clinical imaging probes for microPET and microSPECT imaging".

Molecular imaging using recombinant antibody fragments has emerged over the last decade as a flexible research platform for targeting diagnostic and prognostic biomarkers potentially beneficial for the development of molecular therapies by the biopharmaceutical industry.  ImaginAb's recombinant antibody fragments enable development of tailored, highly specific imaging agents for drug research.  ImaginAb's imaging agent development will benefit from Imanet's PET infrastructure, know-how and nearly 10 years in conducting PET studies with high sensitivity and image resolution for drug development.

Dr. Eric Agdeppa, Imaging Solutions Manager of Imanet, commented, "ImaginAb's technology shows tremendous potential to address a wide range of unmet needs in clinical imaging.  ImaginAb has an extensive pipeline of new products that we are pleased to help develop. We also see synergy between Imanet's capabilities and ImaginAb's rapidly growing pharmaceutical industry clientele."

About ImaginAb

Founded in 2007 by UCLA Faculty (Dr. Rob Reiter and Dr. Anna Wu), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products.  For more information about ImaginAb, visit www.imaginab.com.

About GE Imanet

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.  The company's broad expertise in medical imaging and information technologies, medical diagnostics, drug discovery and performance solutions services help its customers to deliver better care to more people around the world at a lower cost.  Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE).  Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professional and their patients in more than 100 countries.  An integral part of GE Healthcare's Medical Diagnostics business, Imanet™ is a network of clinical PET centers conducting exploratory phase PET imaging studies to aid in the development of products for the pharmaceutical industry since 2001.  For more information about GE Healthcare, visit www.gehealthcare.com and www.imanet.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Dr. Anna Wu

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=91513


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
2. Johnson & Johnson and Crucell Reach Agreement on Intended Public Offer of Euro 24.75 per Ordinary Share of Crucell
3. IGEN AMENDS DISTRIBUTION AGREEMENT AND ANNOUNCES FIRST SPECTRUM BUILD-OUT
4. Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement
5. Clinical Genomics Pty Ltd and The Garvan Institute of Medical Research Enter into Licensing Agreement
6. NeoStem Presented at NASDAQ MarketSite in New York to Discuss Entry Into Merger Agreement With Progenitor Cell Therapy
7. GeneLink Announces HelixLife Private Label Distribution Agreement
8. TOPICA Pharmaceuticals Announces Sublicensing Agreement for Tinea Indication
9. Safran Enters Into a Definitive Agreement With L-1 Identity Solutions for the Purchase of L-1 Biometrics and ID Management Solutions Businesses
10. Drug Development in Arizona Gets Boost Following ASU-Quintiles Agreement
11. Dynamic Ventures Corporation enters into a long-term agreement that brings $50 million annual sales opportunity for wholly owned subsidiary EZ-Build.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... have just published their findings on what they believe could be a new ... summary of the new research. Click here to read it now. ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):